Close Menu

NEW YORK (360Dx) – For a time during the last decade, the drug testing business was something of a gold mine.

With the US opioid epidemic driving an increase in testing, physician practices, pain management clinics, and clinical laboratories billed Medicare and private insurers for billions of dollars per year in urine drug tests and related assays. A 2017 analysis by Kaiser Health News estimated that in 2014, spending on drug testing hit $8.5 billion.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test. 

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.